Endovia Health Sciences entered into an addendum to its existing equity line of credit (ELOC) with C/M Capital Master Fund, LP, increasing the maximum commitment from $35 million to $135 million. The agreement allows the company to sell and issue shares of common stock to the fund from time to time, providing a significant increase in potential liquidity. The addendum also updates terms for sales exceeding the initial 10.875 million shares issued under the original facility.
Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund, LP to amend an existing equity line of credit facility. The amendment increases the beneficial ownership limitation for the investor from 4.99% to 9.99% and waives certain notice requirements. This administrative change modifies the terms of a previously established financing vehicle without disclosing a new capital draw.
Endovia Health Sciences issued 526,582 shares of common stock to C/M Capital Master Fund, LP for gross proceeds of approximately $81,831. The issuance was conducted under an existing equity line of credit (ELOC) agreement dated September 19, 2025.
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined its investigational drug CannEpil qualifies as a 'minor use' under the MUMS program for canine bone cancer pain. This designation allows the company to pursue a conditional approval pathway, which facilitates earlier market availability while additional effectiveness data is collected. The company is targeting a potential U.S. veterinary product launch in 2027.
Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund for a minimum $1 million investment commitment, closing an initial $510,000 via a secured convertible promissory note. Additionally, the company disclosed the issuance of 3,629,250 shares of common stock for gross proceeds of approximately $808,829 under an existing equity line of credit. The funds will support the regulatory advancement and commercialization of CannEpil®.
Endovia Health Sciences $500K Debt Financing with C/M Capital Master Fund, LP
Endovia Health Sciences closed an initial $500,000 tranche of secured convertible debt funding from C/M Capital Master Fund, LP. This financing is part of a larger $1 million commitment intended to accelerate the development and commercialization of CannEpil®, the company's cannabinoid-based pharmaceutical asset.